Estrella Immunopharma, Inc. ESLA
company developing T-cell therapies to address treatment challenges for patients with cancers and autoimmune diseases. Our strategy is
to harness the evolutionary power of the human immune system to provide patients with potentially safer, more efficacious T-cell therapies
compared to traditional CAR-T therapies. Leveraging cutting-edge cellular engineering technologies, we aim to overcome the limitations
of current CAR-T therapies, such as high toxicity and prohibitive costs, so that T-cell therapy treatments can be accessible to a larger
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D | $10.2M | $4.1M | $10.5M | — | — | — |
| SG&A | $2.8M | $3.2M | $663.2K | — | — | — |
| Total operating expenses | $13.1M | $7.3M | $11.1M | — | — | — |
| Operating income | -$13.1M | -$7.3M | -$11.1M | -$1.6M | -$249.1K | — |
| Pre-tax income | -$13.1M | -$7.3M | -$11.1M | -$915.5K | -$247.7K | — |
| Income tax | $838 | $1.6K | — | $80.6K | $0 | — |
| Net income | -$13.1M | -$7.3M | -$11.1M | -$996.1K | -$247.7K | — |
| EPS, basic | -0.35 | -0.27 | -36.35 | — | — | — |
| EPS, diluted | -0.35 | -0.27 | -36.35 | — | — | — |
| Shares, diluted (wtd. avg.) | $36.8M | $27.1M | $305.7K | — | $1.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $1.4M | $916.9K | $2.5M | $4.1M | $478.9K | — |
| Total current assets | $1.7M | $1.6M | $2.8M | $52.4K | $616.0K | — |
| Total assets | $3.2M | $3.1M | $3.0M | $9.7M | $45.8M | — |
| Accounts payable | — | — | — | $329.2K | $3.0K | — |
| Total current liabilities | $13.5M | $3.0M | $9.8M | $1.1M | $73.2K | — |
| Total liabilities | $13.5M | $3.0M | $9.8M | $2.7M | $1.6M | — |
| Retained earnings | -$37.0M | -$23.9M | -$12.2M | -$2.3M | -$1.0M | — |
| Total equity | -$10.4M | $4.3M | -$11.7M | -$1.0M | -$1.0M | $0 |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$1.8M | -$16.1M | -$1.3M | -$1.0M | -$316.2K | — |
| Stock-based compensation | $619.0K | $1.2M | $409.6K | — | — | — |
| Investing cash flow | — | $5.0M | -$273.1K | $36.2M | -$45.2M | — |
| Financing cash flow | $2.3M | $12.8M | — | -$35.6M | $46.0M | — |
| Buybacks | $29.5K | $354.4K | $1.0M | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-050433.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |